Artal Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Artal Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-60,697	Closed	-$426K	–	116
2018 Q2	$426K	Sell	60,697 -89,303	-60%	-$876K	0.01%	103
2018 Q1	$2.13M	Hold	150,000	–	–	0.03%	92
2017 Q4	$1.31M	Sell	150,000 -2,920	-2%	-$28.9K	0.02%	108
2017 Q3	$1.79M	Sell	152,920 -147,080	-49%	-$1.8M	0.03%	98
2017 Q2	$4.19M	Buy	300,000 +100,000	+50%	+$1.14M	0.07%	70
2017 Q1	$2.74M	Buy	+200,000	New	+$2.08M	0.06%	77

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group's SNDX Position: Q3 2018 in Review

Artal Group sold out of Syndax Pharmaceuticals (SNDX) in Q3 2018, closing a stake of 60,697 shares — an estimated $426K sold.

Artal Group first reported a position in SNDX in Q1 2017 and held it in 6 quarters. The position peaked at $4.19M in Q2 2017. 75 funds tracked by Wall St. Rank hold SNDX as of Q3 2018.

Artal Group reported no remaining Syndax Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Artal Group sold 60,697 Syndax Pharmaceuticals shares in Q3 2018, an estimated $426K.
Artal Group first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Artal Group's Syndax Pharmaceuticals position peaked at $4.19M in Q2 2017.
75 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2018.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.